Physicians: If you have a patient who appears to meet the preliminary eligibility criteria below, please get in touch with us about possibly contributing to this trial: https://clinicaltrials.gov/ct2/show/NCT03508609

Inclusion Criteria

  • Men or women age ≥ 18
  • History of effort-induced anginal symptoms and currently experiencing angina at least 3 times per week
  • No obstructive disease on coronary angiogram within 6 months prior to screening which includes any of the following:
    • No obstructive coronary artery disease defined as a coronary artery stenosis less than 40% in the left main coronary artery, or a stenosis 20% or greater but less than 50% in any other epicardial coronary artery.
    • Coronary flow reserve to intracoronary adenosine ≤ 2.5 at screening

Exclusion Criteria

  • Myocardial infarction within 90 days prior to consent or between consent and treatment with CLBS14
  • Prior evidence of obstructive heart disease including history of Percutaneous Coronary Intervention (PCI) and/or Coronary Artery Bypass Grafting (CABG)
  • Planned percutaneous coronary intervention or CABG
  • Diagnosis of other specific cardiac disease such as severe valvular heart disease including:
    • aortic valve area < 1.5,
    • 3+ mitral regurgitation
    • 3+ aortic insufficiency
    • hypertrophic cardiomyopathy
  • Subject currently uses coumadin, dabigatran, apixaban, rivaroxaban, or edoxaban or plans to use one of these agents during the time frame of the trial
  • Subject tests positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C